Sunday, 25 June 2017

No heart risks from Novartis’ Parkinson’s drug

Good news for drug manufacturing company Norvatis as U.S. health regulators
said on Monday that they found
no evidence of increased
cardiovascular risks related to
Novartis AG's treatment, Stalevo,
for Parkinson's disease.

Norvatis are the manufacturer of the drug Stalevo which is used for
treating Parkinson's disease. The story would have been different if
the FDA have discovered that their drug linked to any cardiovascular
disease.

No comments:

Post a Comment

Mental health could cost the global economy up to $16 trillion between 2010 and 2030

According to an expert, mental health disorders are on the rise in every country in the world and could cost the global economy up to $16 tr...